

## Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

Rajnish Mago · Giovanna Forero · William M. Greenberg ·  
Carl Gommoll · Changzheng Chen

Published online: 12 October 2013  
© Springer International Publishing Switzerland 2013

**Erratum to: Clin Drug Investig (2013) 33:761–771**  
**DOI 10.1007/s40261-013-0126-5**

**Page 771, Reference 11**, which previously read:

Bakish D, Gommoll C, Chen C, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study *Int Clin Psychopharmacol*. 2013 (in press).

Should read:

Bakish D, Bose A, Gommoll C, Chen C, Greenberg WM, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. *J Psychiatry Neurosci*. 2013: doi: 10.11503/jpn.130040 (In Press)

---

The online version of the original article can be found under  
doi:[10.1007/s40261-013-0126-5](https://doi.org/10.1007/s40261-013-0126-5).

---

R. Mago (✉)  
Mood Disorders Program, Department of Psychiatry and Human  
Behavior, Thomas Jefferson University, 833 Chestnut St., Suite  
210 E, Philadelphia, PA 19107, USA  
e-mail: rajnish.mago@jefferson.edu

G. Forero · W. M. Greenberg · C. Gommoll  
Clinical Development, Forest Research Institute,  
Jersey City, NJ, USA

C. Chen  
Biostatistics, Forest Research Institute, Jersey City, NJ, USA